<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Insulin glargine (including biosimilars): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Insulin glargine (including biosimilars): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Insulin glargine (including biosimilars): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11545" href="/d/html/11545.html" rel="external">see "Insulin glargine (including biosimilars): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12633" href="/d/html/12633.html" rel="external">see "Insulin glargine (including biosimilars): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F2114346"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Basaglar KwikPen;</li>
<li>Basaglar Tempo Pen;</li>
<li>Lantus;</li>
<li>Lantus SoloStar;</li>
<li>Rezvoglar KwikPen;</li>
<li>Semglee (yfgn);</li>
<li>Semglee [DSC];</li>
<li>Toujeo Max SoloStar;</li>
<li>Toujeo SoloStar</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868729"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Basaglar;</li>
<li>Basaglar KwikPen;</li>
<li>Lantus;</li>
<li>Lantus SoloStar;</li>
<li>Semglee;</li>
<li>Toujeo Doublestar;</li>
<li>Toujeo SoloStar</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F2114349"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Insulin, Long-Acting</li></ul></div>
<div class="block doa drugH1Div" id="F2110691"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Insulin glargine-yfgn (Semglee, generic) has been approved as a biosimilar to Lantus (insulin glargine); in Canada, Semglee is also approved as a biosimilar to Lantus (insulin glargine).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Insulin glargine is a basal insulin. Insulin requirements vary between patients; monitor glucose levels frequently and individualize dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc2823b3-202c-4a44-a2d1-58b5084839e6">Diabetes mellitus, type 1, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 1, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Insulin glargine must be used concomitantly with rapid- or short-acting insulins (ie, multiple daily injection regimen). <b>The total daily doses (TDDs) presented below are expressed as the total units/kg/day of all insulin formulations (basal and prandial) combined.</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General insulin dosing</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Initial TDD:</i></b>
<b>SUBQ:</b> 0.4 to 0.5 units/kg/day in divided doses; conservative initial doses of 0.2 to 0.4 units/kg/day may be considered to avoid hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25869408','lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25869408','lexi-content-ref-ADA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Usual TDD maintenance range:</i></b>
<b>SUBQ:</b> 0.4 to 1 units/kg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Division of TDD (multiple daily injections):</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">Basal insulin: <b>SUBQ:</b> 40% to 50% of the TDD administered as insulin glargine once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25869408','lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25869408','lexi-content-ref-ADA.2021'])">Ref</a></span>). In patients with inadequate basal insulin coverage with once-daily dosing, administration of U-100 (100 units/mL) formulations in 2 divided doses may be beneficial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16911626','lexi-content-ref-20345066']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16911626','lexi-content-ref-20345066'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Prandial insulin: <b>SUBQ: </b>The remaining portion (ie, 50% to 60%) of the TDD is then divided and administered before, at, or just after mealtimes, depending on the formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25869408','lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25869408','lexi-content-ref-ADA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage adjustment for glycemic control: SUBQ:</b> Increase or decrease daily dose by 10% to 20% once or twice weekly (eg, every 3 or 7 days) to maintain premeal and bedtime glucose in target range; avoid more frequent dosage adjustment to minimize hypoglycemia risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-22575407']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-22575407'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Preoperative dosage adjustment: </b>Dose reductions are applied to the morning and/or evening insulin glargine doses as follows:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Evening scheduled dosage adjustment:</i>
<b>SUBQ:</b> Reduce insulin glargine dose by 10% to 25% the evening before the procedure; may administer the full dose in patients whose glucose levels are generally elevated (eg, &gt;200 mg/dL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22223765','lexi-content-ref-Khan.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22223765','lexi-content-ref-Khan.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Morning scheduled dosage adjustment:</i>
<b>SUBQ:</b> Administer one-half to two-thirds of the total morning insulin dose (basal + prandial) as insulin glargine the morning of the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Khan.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Khan.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Preferred in patients with symptomatic hyperglycemia (eg, weight loss, polydipsia, polyuria) or ketonuria; may also be used in patients with severe hyperglycemia (eg, fasting glucose &gt;250 mg/dL, random glucose consistently &gt;300 mg/dL, HbA<sub>1c</sub> &gt;9%), or if glycemic goals are not met despite adequately titrated metformin with or without other noninsulin agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-Wexler.1'])">Ref</a></span>). Consider discontinuation or a dose reduction of sulfonylureas and thiazolidinediones when initiating basal insulin therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30291106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30291106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Initial:</i> SUBQ:</b> 10 units once daily <b>or</b> 0.1 to 0.2 units/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-Manu.1'])">Ref</a></span>). In patients with HbA<sub>1c</sub> &gt;8%, fasting plasma glucose &gt;250 mg/dL, or insulin resistance, 0.2 to 0.3 units/kg/day is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-Wexler.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-Wexler.2'])">Ref</a></span>). Some experts use a minimum of 10 units/day and do not exceed 20 units/day for the initial dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wexler.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wexler.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Dosage adjustment</b>
<b>:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>For persistently elevated fasting plasma glucose: SUBQ:</b> Increase daily dose by 2 to 4 units <b>or </b>by 10% to 20% every 2 to 3 days to achieve fasting plasma glucose target while avoiding hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-ADA.2021','lexi-content-ref-Wexler.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-ADA.2021','lexi-content-ref-Wexler.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>For elevated HbA<sub>1c </sub>despite achieving fasting plasma glucose target:</b>
<b>SUBQ:</b> Encourage lifestyle modifications. Consider adding other medications (eg, a glucagon-like peptide-1 receptor agonist, prandial insulin before the largest meal). In patients taking high doses (eg, &gt;80 units/day) of U-100 (100 units/mL) formulations once daily, an alternative is to switch to a twice-daily regimen by administering the current daily dose in 2 equally divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30619716','lexi-content-ref-20144488','lexi-content-ref-Wexler.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30619716','lexi-content-ref-20144488','lexi-content-ref-Wexler.2'])">Ref</a></span>). In some patients, higher insulin glargine doses (eg, &gt;0.5 units/kg/day) may provide diminishing additional improvements in HbA<sub>1c</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-ADA.2021','lexi-content-ref-26566714','lexi-content-ref-30724009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-ADA.2021','lexi-content-ref-26566714','lexi-content-ref-30724009'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>For hypoglycemia:</b>
<b>SUBQ:</b> For unexplained mild to moderate hypoglycemia, consider decreasing daily dose by 10% to 20% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021'])">Ref</a></span>); for severe hypoglycemia requiring assistance from another person or blood glucose &lt;40 mg/dL, consider decreasing daily dose by 20% to 50% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-Wexler.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-Wexler.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Dosage adjustment when adding prandial insulin:</b>
<b>SUBQ:</b> In patients whose glucose levels are close to target (eg, HbA<sub>1c</sub> &lt;8%), consider decreasing the basal insulin daily dose by 4 units <b>or</b> by 10% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Preoperative dosage adjustment: </b>Dose reductions are applied to the morning and/or evening insulin glargine doses as follows:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Evening scheduled dosage adjustment:</i>
<b>SUBQ:</b> Reduce insulin glargine dose by 10% to 25% the evening before the procedure; may administer the full dose if preoperative hypoglycemia risk is low (eg, glucose levels generally &gt;200 mg/dL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22223765','lexi-content-ref-Khan.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22223765','lexi-content-ref-Khan.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Morning scheduled dosage adjustment:</i>
<b>SUBQ:</b> For patients not using prandial insulin, reduce insulin glargine dose by 10% to 25% the morning of the procedure; may administer the full dose if preoperative hypoglycemia risk is low (eg, glucose levels generally &gt;200 mg/dL). For patients using prandial insulin, omit prandial insulin after fasting begins and administer one-half to two-thirds of the total morning insulin dose (basal + prandial) as insulin glargine the morning of the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22223765','lexi-content-ref-Khan.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22223765','lexi-content-ref-Khan.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70b35ef8-5589-4fcf-8fcb-ab71c5c307ec">Hyperglycemia, hospitalized patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperglycemia, hospitalized patients (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use in patients with persistent hyperglycemia (eg, blood glucose ≥140 to 180 mg/dL for &gt;12 to 24 hours) with or without a history of diabetes; patients with type 1 diabetes require basal insulin therapy regardless of glucose levels or nutritional intake. Dose is individualized; use of institution-specific protocols to achieve glycemic targets and minimize hypoglycemia is encouraged (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-23164767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-23164767'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial (insulin glargine 100 units/mL formulations only):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients not receiving basal insulin prior to hospitalization: </i>
<b>SUBQ:</b> 0.1 to 0.3 units/kg administered once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14747243','lexi-content-ref-22223765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14747243','lexi-content-ref-22223765'])">Ref</a></span>). <b>Note: </b>Consider doses at the lower end of this range in patients ≥70 years of age and in those with renal impairment; consider doses at the higher end of this range in patients with glucose levels &gt;200 mg/dL or who are receiving glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22223765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22223765'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients receiving basal insulin prior to hospitalization: </i>
<b>SUBQ:</b> Continue the prehospitalization basal insulin dose; an empiric 20% to 50% dose reduction may be considered in patients whose prehospitalization glucose levels were within target range, <b>or </b>in patients with impaired renal function, poor nutritional intake, or admission glucose levels &lt;100 mg/dL; higher doses may be required in patients receiving glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-Inzucchi.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-Inzucchi.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients transitioning from an IV insulin infusion: </i>
<b>SUBQ:</b> Refer to institution-specific protocols. In patients whose insulin requirements are known, prior basal insulin regimen may be resumed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Inzucchi.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Inzucchi.2021'])">Ref</a></span>). In patients whose insulin requirements are not known, total daily dosage may be estimated as 60% to 80% of the mean IV insulin dosage over the prior 6 hours, or by using weight-based dosing of 0.1 to 0.3 units/kg administered once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14747243','lexi-content-ref-22223765','lexi-content-ref-23164767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14747243','lexi-content-ref-22223765','lexi-content-ref-23164767'])">Ref</a></span>). <b>Note:</b> Administer initial dose of basal insulin ≥2 to 4 hours before discontinuing IV insulin infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-23164767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-23164767'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage adjustment: SUBQ:</b> Adjust daily dose by 10% to 20% every 2 to 3 days to achieve glycemic targets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Inzucchi.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Inzucchi.2021'])">Ref</a></span>). Consider reducing dosage for glucose levels &lt;100 mg/dL to avoid hypoglycemia; in patients with glucose levels &lt;40 mg/dL, larger dose reductions (eg, by 20% to 40%) may be needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-19454396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-19454396'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Conversion between basal insulin products:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Conversion from NPH insulin to insulin glargine:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Converting from once-daily NPH insulin to insulin glargine: <b>SUBQ:</b> Initial: May be substituted on an equivalent unit-per-unit basis.</p>
<p style="text-indent:-2em;margin-left:6em;">Converting from twice-daily NPH insulin to insulin glargine: <b>SUBQ: </b>Initial: Administer 80% of the total daily NPH dose as insulin glargine once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Conversion from insulin detemir to insulin glargine:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Converting from once-daily insulin detemir to insulin glargine U-300 (300 units/mL): <b>SUBQ:</b> Initial: May be substituted on an equivalent unit-per-unit basis.</p>
<p style="text-indent:-2em;margin-left:6em;">Converting from once-daily insulin detemir to insulin glargine U-100 (100 units/mL) formulations: <b>SUBQ:</b> Initial: Administer 80% to 90% of the total daily insulin detemir dose as insulin glargine once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kocurek.2018','lexi-content-ref-Wexler.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kocurek.2018','lexi-content-ref-Wexler.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Converting from twice-daily insulin detemir to insulin glargine: <b>SUBQ:</b> Initial: Administer 80% to 90% of the total daily insulin detemir dose as insulin glargine once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wexler.2','lexi-content-ref-Toujeo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wexler.2','lexi-content-ref-Toujeo.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Conversion between insulin glargine products (Toujeo, Lantus, Basaglar, or insulin glargine-yfgn [Semglee, generic]):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">Conversion from once-daily Toujeo (300 units/mL) to once-daily Lantus, Basaglar, or insulin glargine-yfgn (Semglee, generic) (100 units/mL): <b>SUBQ:</b> Initial: Administer 80% of the Toujeo dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Conversion from once-daily Lantus to once-daily Toujeo or once-daily Basaglar: <b>SUBQ:</b> Initial: May be substituted on an equivalent unit-per-unit basis; a higher daily dosage of Toujeo will generally be required to achieve the same level of glycemic control as with Lantus.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Conversion between Toujeo SoloStar and Toujeo Max SoloStar (or Toujeo DoubleStar [Canadian product]):</i></b>
<b>SUBQ:</b> Initial: If previous dose was an odd number, the dose should be increased or decreased by 1 unit.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991431"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Recommendations are expert opinion derived from Aronoff 2007, Baldwin 2012, Biesenbach 2003, Kulozik 2013, Rahhal 2019, Rajput 2017, and Rashid 2004 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-22699288','lexi-content-ref-12873291','lexi-content-ref-23997930','lexi-content-ref-31162534','lexi-content-ref-28315574','lexi-content-ref-Rashid.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-22699288','lexi-content-ref-12873291','lexi-content-ref-23997930','lexi-content-ref-31162534','lexi-content-ref-28315574','lexi-content-ref-Rashid.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial dosing:</b>
<b>SUBQ:</b> When initiating insulin glargine, the following recommendations based on kidney function are suggested:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>eGFR ≥50 mL/minute/1.73 m<sup>2</sup>:</b> No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>eGFR &gt;10 to &lt;50 mL/minute/1.73 m<sup>2</sup>:</b> Administer 75% of the usual starting dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>eGFR ≤10 mL/minute/1.73 m<sup>2</sup>:</b> Administer 50% of the usual starting dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage adjustment: SUBQ: </b>Dose adjustments should generally follow the indication-specific recommendations as described in the adult dosing section but titrated more gradually; in patients with eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>, use with caution and monitor glucose levels frequently.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b>
<b>Initial dosing: SUBQ:</b> When initiating insulin glargine, administer 50% of the usual starting dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Dose adjustments should generally follow the indication-specific recommendations as described in the adult dosing section but titrated more gradually; in patients experiencing hypoglycemia, consider more aggressive dose reductions (eg, by 25% to 40%) depending on severity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-20215452','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-20215452','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b>
<b>Initial dosing: SUBQ</b>: When initiating insulin glargine, administer 50% of the usual starting dose with slow titration and close monitoring of blood glucose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>
<b>SUBQ: </b>Use is not recommended due to long duration of action; use of continuous IV insulin infusion is preferred in critically ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Patients requiring basal insulin prior to their acute illness should be transitioned back to SUBQ basal insulin therapy (eg, insulin glargine) once the acute illness has stabilized and CRRT is discontinued (initially at a reduced dose based on patient specific factors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b>
<b>SUBQ:</b> Use is not recommended in critically ill patients due to long duration of action; use of continuous IV insulin infusion is preferred in critically ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-Expert.DOR'])">Ref</a></span>). When initiating insulin glargine in patients who have clinically stabilized and are receiving PIRRT as a transition back to intermittent hemodialysis, consider administering 50% of the usual starting dose with slow titration and close monitoring of blood glucose. Patients requiring basal insulin prior to their acute illness should be transitioned back to SUBQ basal insulin therapy (eg, insulin glargine) once the acute illness has stabilized (initially at a reduced dose based on patient-specific factors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988710"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>
<div class="block doe drugH1Div" id="F2110692"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F2307975"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12633" href="/d/html/12633.html" rel="external">see "Insulin glargine (including biosimilars): Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Insulin glargine is a long-acting insulin. Insulin glargine is approximately equipotent to human insulin, but has a slower onset, no pronounced peak, and a longer duration of activity. Insulin doses should be individualized based on patient needs; adjustments may be necessary with changes in physical activity, meal patterns, acute illness, or with changes in renal or hepatic function. Insulin requirements vary dramatically between patients and dictates frequent monitoring and close medical supervision. Insulin regimens vary widely by region, practice, and institution; consult institution-specific guidelines.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5956846-9e6c-4def-954b-a126316b2bbe">Diabetes mellitus, type 1</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 1:</b> Children and Adolescents: <b>Note:</b> For basal insulin coverage, long-acting insulin analogs are preferred over insulin NPH due to decreased risk of hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25869408','lexi-content-ref-ADA.2019','lexi-content-ref-24935775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25869408','lexi-content-ref-ADA.2019','lexi-content-ref-24935775'])">Ref</a></span>). Insulin glargine must be used in combination with a rapid or short-acting insulin. The daily doses presented are expressed as the <b>total units/kg/day of all insulin formulations</b> used.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Insulin glargine-specific dosing: Note:</b> All pediatric patients should have rapid-acting or regular insulin available for crisis management (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29999222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29999222'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial dose:</i> Children ≥6 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Lantus, Basaglar: SubQ: Approximately one-third of the total daily insulin requirement administered once daily; a rapid-acting or short-acting insulin should also be used to complete the balance (~<sup>2</sup>/<sub>3</sub>) of the total daily insulin requirement. Adjust dosage according to patient response.</p>
<p style="text-indent:-2em;margin-left:8em;">Toujeo: SubQ: Approximately one-third to one-half of the total daily insulin requirement administered once daily; a rapid-acting or short-acting insulin should also be used to complete the balance of the total daily insulin requirement. Adjust dosage according to patient response.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General insulin dosing: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial total daily insulin: </i>SubQ: Initial: 0.4 to 0.5 units/kg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25869408','lexi-content-ref-ADA.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25869408','lexi-content-ref-ADA.2019'])">Ref</a></span>); Usual range: 0.4 to 1 units/kg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25869408','lexi-content-ref-ADA.2019','lexi-content-ref-15616254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25869408','lexi-content-ref-ADA.2019','lexi-content-ref-15616254'])">Ref</a></span>); lower doses (0.25 units/kg/day) may be used especially in young children to avoid potential hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26472948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26472948'])">Ref</a></span>); higher doses may be necessary for some patients (eg, obese, concomitant steroids, puberty, sedentary lifestyle, following diabetic ketoacidosis presentation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25869408','lexi-content-ref-ADA.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25869408','lexi-content-ref-ADA.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Usual total daily maintenance range:</i> SubQ: Doses must be individualized; however, an estimate can be determined based on phase of diabetes and level of maturity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29999222','lexi-content-ref-28726299']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29999222','lexi-content-ref-28726299'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Partial remission phase (Honeymoon phase): &lt;0.5 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">Prepubertal children (not in partial remission):</p>
<p style="text-indent:-2em;margin-left:10em;">Infants ≥6 months and Children ≤6 years: 0.4 to 0.8 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥7 years: 0.7 to 1 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">Pubescent Children and Adolescents: During puberty, requirements may substantially increase to &gt;1 unit/kg/day and in some cases up to 2 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Division of daily insulin requirement (multiple daily injections): </i></p>
<p style="text-indent:-2em;margin-left:8em;">Basal insulin: Generally, ~30% to 50% of the total daily insulin is given as basal insulin (intermediate- or long-acting) in 1 to 2 daily injections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25869408','lexi-content-ref-ADA.2019','lexi-content-ref-29999222','lexi-content-ref-Peters.2013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25869408','lexi-content-ref-ADA.2019','lexi-content-ref-29999222','lexi-content-ref-Peters.2013'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Prandial insulin: The remaining portion of the total daily dose is then divided and administered before or at mealtimes (depending on the formulation) as a rapid-acting (eg, aspart, glulisine, lispro) or short-acting (regular). In most type 1 patients, the use of a rapid-acting insulin analog is preferred over regular insulin to reduce hypoglycemia risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25869408','lexi-content-ref-ADA.2019','lexi-content-ref-24935775','lexi-content-ref-29999222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25869408','lexi-content-ref-ADA.2019','lexi-content-ref-24935775','lexi-content-ref-29999222'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Dosage titration:</b> Treatment and monitoring regimens must be individualized to maintain premeal and bedtime glucose in target range; titrate dose to achieve glucose control and avoid hypoglycemia. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Surgical patients </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30039617']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30039617'])">Ref</a></span>): <b>Note: </b>Diabetic patients should be scheduled as the first case of the day.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Minor surgeries:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Morning procedure: Administer the usual insulin glargine dose (if usually given in the morning); may consider reducing dose to 70% to 80% of usual dose if preoperative evaluation shows low morning blood glucose values. Alternatively, may administer IV insulin (regular) infusion; begin IV fluids containing dextrose; in general rapid acting insulin should be omitted until after surgery and patient is able to eat unless it is needed to correct significant hyperglycemia and/or significant ketone (&gt;0.1 mmol/mol) production is present.</p>
<p style="text-indent:-2em;margin-left:10em;">Afternoon procedure: Administer the usual morning dose of insulin glargine (if usually given in the morning).</p>
<p style="text-indent:-2em;margin-left:10em;">Postprocedure: Once normal oral intake is achieved, resume usual insulin regimen; monitor closely due to risk of changes related to surgery (ie, postoperative stress, medication changes, inactivity).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Major surgeries:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Evening prior to surgery: If patient normally receives evening insulin doses, administer 50% to 100% of the usual evening and/or bedtime insulin glargine; patients on continuous subcutaneous insulin infusion (CSII) may continue normal insulin basal rates overnight; if there is a concern for hypoglycemia, basal rate may be reduced by 20% at ~3 am.</p>
<p style="text-indent:-2em;margin-left:10em;">Morning of surgery: Omit morning insulin (short- and long-acting) and start IV insulin (regular) infusion and IV fluids containing dextrose; patients on CSII should discontinue CSII when IV insulin infusion is started; once normal oral intake is resumed, then resume usual insulin regimen; monitor closely due to risk of changes related to surgery (ie, postoperative stress, medication changes, inactivity).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="570f091a-c1c1-46a6-9d95-172eadddf365">Diabetes mellitus, type 2</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2:</b> Limited data available: <b>Note: </b>The goal of therapy is to achieve an HbA<sub>1c</sub> &lt;7% as quickly as possible using the safe titration of medications.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Toujeo-specific dosing:</b> Children ≥6 years and Adolescents: SubQ: Initial: 0.2 units/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General insulin dosing:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Newly diagnosed patients: Note:</b> Recommended for use in metabolically unstable patients (eg, plasma glucose ≥250 mg/dL, HbA<sub>1c</sub> &gt;8.5%, and symptoms excluding acidosis) while metformin is initiated and titrated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30425094','lexi-content-ref-ADA.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30425094','lexi-content-ref-ADA.2019'])">Ref</a></span>); may also be used for patients with ketosis/ketoacidosis/ketonuria to correct the hyperglycemia and the metabolic derangement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30425094','lexi-content-ref-29999228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30425094','lexi-content-ref-29999228'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥10 years and Adolescents: SubQ:</p>
<p style="text-indent:-2em;margin-left:10em;">Initial therapy: 0.25 to 0.5 units/kg/dose once daily; titrate every 2 to 3 days as needed based on plasma glucose; use in combination with lifestyle changes and metformin to achieve goals.</p>
<p style="text-indent:-2em;margin-left:10em;">Subsequent therapy:</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Glycemic goal achieved:</i> Once initial goal reached, insulin should be slowly tapered over 2 to 6 weeks by decreasing the insulin dose by 10% to 30% every few days and the patient transitioned to lowest effective doses or metformin monotherapy if able (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23359574','lexi-content-ref-ADA.2019','lexi-content-ref-30425094','lexi-content-ref-29999228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23359574','lexi-content-ref-ADA.2019','lexi-content-ref-30425094','lexi-content-ref-29999228'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Failure to achieve glycemic goal:</i> In patients who fail to achieve glycemic goals with insulin glargine (up to 1.5 units/kg/day) and maximum metformin dose, may consider dividing insulin glargine dose into multiple daily injections (eg, twice daily) and/or initiating prandial insulin (regular insulin or rapid-acting insulin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30425094','lexi-content-ref-29999228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30425094','lexi-content-ref-29999228'])">Ref</a></span>). <b>Note: </b>Insulin resistance is common with type 2 diabetes and doses &gt;1.5 units/kg/day may be necessary to achieve glycemic control especially in patients with high A<sub>1c</sub> and patients in mid to late puberty; may consider use of more concentrated insulin glargine preparations (U-300 [Toujeo]) to avoid large volume injections that may affect medication adherence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30425094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30425094'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Patients on established therapy: Note: </b>Recommended for use when glycemic goals can no longer be met using metformin alone, or if contraindications or intolerable side effects of metformin develop (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30425094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30425094'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥10 years and Adolescents: SubQ: Initial: 0.25 to 0.5 units/kg/dose once daily; may be used alone or in combination with metformin (if not contraindicated); may be titrated as needed based on plasma glucose. If glycemic goals are not achieved at 1.5 units/kg/day evaluate adherence; if adherence confirmed, may consider dividing insulin glargine dose into multiple daily injections (eg, twice daily) and/or initiating prandial insulin (regular insulin or rapid-acting insulin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30425094','lexi-content-ref-29999228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30425094','lexi-content-ref-29999228'])">Ref</a></span>). <b>Note:</b> Insulin resistance is common with type 2 diabetes and doses &gt;1.5 units/kg/day may be necessary to achieve glycemic control especially in patients with high A<sub>1c</sub> and patients in mid to late puberty; may consider use of more concentrated insulin glargine preparations (U-300 [Toujeo]) to avoid large volume injections that may affect medication adherence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30425094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30425094'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Conversion to insulin glargine from NPH insulin:</b></i> Children ≥2 years and Adolescents: SubQ: <b>Note:</b> Limited data available in children &lt;6 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16126116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16126116'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Converting from once-daily NPH insulin to insulin glargine: May be substituted on an equivalent unit-per-unit basis.</p>
<p style="text-indent:-2em;margin-left:4em;">Converting from twice-daily NPH insulin to insulin glargine: Initial dose: Use 80% of the total daily dose of NPH (eg, 20% reduction); administer once daily; adjust dosage according to patient response.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Conversion between Toujeo, Lantus, or Basaglar:</i></b> Children ≥6 years and Adolescents: SubQ:</p>
<p style="text-indent:-2em;margin-left:4em;">Conversion from once-daily Toujeo to once-daily Lantus or once-daily Basaglar: Initial dose: Use 80% of the dose of Toujeo (eg, 20% reduction); adjust dosage according to patient blood glucose response.</p>
<p style="text-indent:-2em;margin-left:4em;">Conversion from once-daily Lantus to once-daily Toujeo or once-daily Basaglar: Initial dose: May be substituted on an equivalent unit-per-unit basis; however, generally a higher daily dosage of Toujeo will be required to achieve the same level of glycemic control as with Lantus.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Conversion between Toujeo SoloStar and Toujeo Max SoloStar:</i></b> Children ≥6 years and Adolescents: SubQ: If previous dose was an odd number, the dose should be increased or decreased by 1 unit to accommodate the 2 unit dosing increment on the Max SoloStar device.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51114015"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; insulin requirements are reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>
<div class="block dohp drugH1Div" id="F51114016"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>
<div class="block adr drugH1Div" id="F2110684"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidence rates are from glargine administered with concomitant antidiabetic agents (insulin or oral products).</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (20%), peripheral edema (≤20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Severe hypoglycemia (Type I on combination regimens: 4% to 69%; Type II on combination regimens: ≤37%; monotherapy in adults ≥50 years old: 6% [ORIGIN trial])</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (12% to 44%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (9% to 24%), influenza (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (14%), back pain (13%), limb pain (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cataract (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (15%), cough (12%), nasopharyngitis (6% to 16%), sinusitis (19%), upper respiratory tract infection (5% to 29%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (6% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Retinal vascular disease (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (children and adolescents: 8%), rhinitis (children and adolescents: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Local: Injection-site reaction (including erythema at injection site, hypertrophy at injection site, inflammation at injection site, injection-site pruritus, lipoatrophy at injection site, localized edema, swelling at injection site, urticaria at injection site)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Sodium retention, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Endocrine &amp; metabolic: Amyloidosis (localized cutaneous at injection site)</p></div>
<div class="block coi drugH1Div" id="F2110683"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to insulin glargine or any component of the formulation; during episodes of hypoglycemia</p></div>
<div class="block war drugH1Div" id="F2114356"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Glycemic control: Hyper- or hypoglycemia may result from changes in insulin strength, manufacturer, type, and/or administration method. The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from changes in meal pattern (eg, macronutrient content, timing of meals), changes in the level of physical activity, increased work or exercise without eating, or changes to coadministered medications. Use of long-acting insulin preparations (eg, insulin degludec, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Patients with renal or hepatic impairment may be at a higher risk. Symptoms differ in patients and may change over time in the same patient; awareness may be less pronounced in those with long-standing diabetes, diabetic neuropathy, patients taking beta-blockers, or in those who experience recurrent hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage, or even death. Insulin requirements may be altered during illness, emotional disturbances, or other stressors. Instruct patients to use caution with ethanol; may increase risk of hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Severe, life-threatening allergic reactions, including anaphylaxis, may occur. If hypersensitivity reactions occur, discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypokalemia: Insulin (especially IV insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium and supplement potassium when necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">– Type 2 diabetes, hypoglycemia: Closely monitor insulin dose requirement throughout active weight loss with a goal of eliminating antidiabetic therapy or transitioning to agents without hypoglycemic potential; hypoglycemia after gastric bypass, sleeve gastrectomy, and gastric band may occur (Mechanick 2019). Insulin secretion and sensitivity may be partially or completely restored early after these procedures (gastric bypass is most effective, followed by sleeve and finally band) (Korner 2009; Peterli 2012). Monitoring of hospital insulin requirements is recommended to guide discharge insulin dose. Rates and timing of type 2 diabetes improvement and resolution vary widely by patient; insulin dose reduction of 75% has been suggested after gastric bypass for patients without severe β-cell failure (fasting c-peptide &lt;0.3 nmol/L) (Cruijsen 2014).</p>
<p style="text-indent:-2em;margin-left:6em;">– Weight gain: Insulin therapy is preferred if antidiabetic therapy is required during the perioperative period (Mechanick 2019). Evaluate risk versus benefit of long-term postoperative use, and consider alternative therapy due to potential for insulin-induced weight gain (Apovian 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac disease: Concurrent use with peroxisome proliferator-activated receptor (PPAR)-gamma agonists, including thiazolidinediones, may cause dose-related fluid retention and lead to or exacerbate heart failure (HF), particularly when used in combination with insulin. If PPAR-gamma agonists are prescribed, monitor for signs and symptoms of HF. If HF develops, consider PPAR-gamma agonist dosage reduction or therapy discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetic ketoacidosis: Should not be used in patients with diabetic ketoacidosis; use of a rapid-acting or short-acting insulin is required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage requirements may be reduced.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment. Dosage requirements may be reduced.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hospitalized patients: Prolonged use of a sliding scale insulin regimen in the inpatient setting is strongly discouraged. In the critical care setting, continuous IV insulin infusion (insulin regular) has been shown to best achieve glycemic targets. In noncritically ill patients with either poor oral intake or taking nothing by mouth, basal insulin use is preferred, with correctional doses (insulin regular or rapid-acting insulin) as needed. In noncritically ill patients with adequate nutritional intake, a combination of basal insulin along with nutritional and correctional components (insulin regular or rapid-acting insulin) is preferred. An effective insulin regimen will achieve the goal glucose range without the risk of severe hypoglycemia. A blood glucose value &lt;70 mg/dL should prompt a treatment regimen review and change, if necessary, to prevent further hypoglycemia (ADA 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Insulin glargine is a clear solution, but it is <b>NOT</b> intended for IV or IM administration or via an insulin pump.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.</p></div>
<div class="block dosfc drugH1Div" id="F57559563"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">Basaglar Tempo Pen: The Tempo Pen contains a component that allows for data connectivity when used with a compatible transmitter. Consult the prescribing information for additional information.</p></div>
<div class="block foc drugH1Div" id="F2104245"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lantus: 100 units/mL (10 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Semglee: 100 units/mL (10 mL [DSC]) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Semglee (yfgn): Insulin glargine-yfgn 100 units/mL (10 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 units/mL (10 mL [DSC]); Insulin glargine-yfgn 100 units/mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Basaglar KwikPen: 100 units/mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Basaglar Tempo Pen: 100 units/mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lantus SoloStar: 100 units/mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rezvoglar KwikPen: Insulin glargine-aglr 100 units/mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Semglee: 100 units/mL (3 mL [DSC]) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Semglee (yfgn): Insulin glargine-yfgn 100 units/mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Toujeo Max SoloStar: 300 units/mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Toujeo SoloStar: 300 units/mL (1.5 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 units/mL (3 mL [DSC]); 300 units/mL (1.5 mL, 3 mL); Insulin glargine-yfgn 100 units/mL (3 mL)</p></div>
<div class="block geq drugH1Div" id="F2114347"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F3422169"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Insulin Glargine-yfgn Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $7.56</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Lantus Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $7.71</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Semglee (yfgn) Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $32.33</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Basaglar KwikPen Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $26.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Basaglar Tempo Pen Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $26.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Insulin Glargine-yfgn Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $7.36</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Lantus SoloStar Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $7.71</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Rezvoglar KwikPen Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $7.36</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Semglee (yfgn) Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $32.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Toujeo Max SoloStar Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 units/mL (per mL): $114.31</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Toujeo SoloStar Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 units/mL (per mL): $114.28</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868730"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lantus: 100 units/mL (10 mL) [contains cresol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Cartridge, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Basaglar: 100 units/mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lantus: 100 units/mL (3 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Basaglar KwikPen: 100 units/mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lantus SoloStar: 100 units/mL (3 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Semglee: 100 units/mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Toujeo Doublestar: 300 units/mL (3 mL) [contains metacresol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Toujeo SoloStar: 300 units/mL (1.5 mL) [contains metacresol]</p></div>
<div class="block adm drugH1Div" id="F2110693"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Do not use if solution is viscous or cloudy; use only if clear and colorless with no visible particles. Insulin glargine should be administered consistently at the same time each day. Cold injections should be avoided. SUBQ administration is usually made into the thighs, arms, buttocks, or abdomen; absorption rates vary amongst injection sites; be consistent with area used while rotating injection sites within the same region to avoid lipodystrophy or localized cutaneous amyloidosis. Rotating from an injection site where lipodystrophy/cutaneous amyloidosis is present to an unaffected site may increase risk of hypoglycemia. Do not dilute or mix insulin glargine with any other insulin formulation or solution.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Insulin glargine prefilled pens are available in concentrations of 100 units/mL and 300 units/mL. Prefilled pens are calibrated to display the actual insulin units administered (no dosage conversion needed) and will administer up to 80 units per injection, in 1 unit increments (Lantus SoloStar, Basaglar KwikPen, Basaglar Tempo Pen, Toujeo SoloStar, insulin glargine-yfgn [Semglee, generic]) or up to 160 units per injection, in 2 unit increments (Toujeo Max SoloStar, Toujeo DoubleStar [Canadian product]). Toujeo Max SoloStar and Toujeo DoubleStar (Canadian product) prefilled pens are only recommended for use in patients requiring at least 20 units of insulin glargine per day. Do not use a syringe to withdraw concentrated insulin glargine (300 units/mL) from a prefilled pen for administration. For prefilled pens, prime the needle with 2 units (Basaglar, Lantus, insulin glargine-yfgn [Semglee, generic]) or 3 units (Toujeo) or 4 units (Toujeo Max) before each injection (using a new needle). Once injected, continue to depress the button until the dial has returned to 0 <b>and </b>for an additional 5 seconds (Basaglar, Toujeo, Toujeo Max) or 10 seconds (Lantus, insulin glargine-yfgn [Semglee, generic]). Then, remove the needle. Cartridges (Canadian product) are to be used only with reusable pens recommended by the manufacturer (refer to product labeling).</p></div>
<div class="block admp drugH1Div" id="F52614089"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">SubQ: Do not use if solution is viscous or cloudy; use only if clear and colorless with no visible particles. Administer consistently at the same time each day. Cold injections should be avoided. SubQ administration is usually made into the thighs, arms, buttocks, or abdomen; absorption rates vary amongst injection sites; be consistent with area used while rotating injection sites within the same region to avoid lipodystrophy or localized cutaneous amyloidosis. Rotating from an injection site where lipodystrophy/cutaneous amyloidosis is present to an unaffected site may increase risk of hypoglycemia. Do not mix with any other insulin or solution. Do not administer IV or in an insulin pump.</p>
<p style="text-indent:0em;margin-top:2em;">Insulin glargine prefilled pens are available in concentrations of 100 units/mL and 300 units/mL. Prefilled pens are calibrated to display the actual insulin units administered (no dosage conversion needed) and will administer up to 80 units per injection, in 1 unit increments (eg, Lantus SoloStar, Basaglar KwikPen, Basaglar Tempo Pen, Toujeo SoloStar) or up to 160 units per injection, in 2 unit increments (eg, Toujeo Max SoloStar). Toujeo Max SoloStar prefilled pens are recommended for use in patients requiring at least 20 units of insulin glargine per day. Do not use a syringe to withdraw concentrated insulin glargine (300 units/mL) from a prefilled pen for administration. For prefilled pens, prime the needle according to manufacturer labeling (eg, Basaglar, Lantus, Semglee: 2 units; Toujeo: 3 units; Toujeo Max: 4 units) before each injection using a new needle. Once injected, continue to depress the button until the dial has returned to 0 and for an additional 5 seconds (eg, Basaglar, Toujeo, Toujeo Max) or 10 seconds (eg, Lantus, Semglee) and then, remove the needle.</p></div>
<div class="block use drugH1Div" id="F2114351"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, types 1 and 2, treatment:</b> To improve glycemic control in pediatric patients ≥6 years of age and adults with type 1 diabetes mellitus; to improve glycemic control in pediatric patients ≥6 years of age (Toujeo only) and adults with type 2 diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Insulin glargine-yfgn (Semglee, generic) has been approved as a biosimilar to Lantus (insulin glargine). In Canada, Semglee is also approved as a biosimilar to Lantus (insulin glargine).</p></div>
<div class="block off-label drugH1Div" id="F55567544"><span class="drugH1">Use: Off-Label: Adult</span><p>Hyperglycemia in hospitalized patients</p></div>
<div class="block mst drugH1Div" id="F2114344"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Insulin glargine may be confused with insulin glulisine.</p>
<p style="text-indent:-2em;margin-left:4em;">Lantus may be confused with latanoprost, Latuda, Xalatan.</p>
<p style="text-indent:-2em;margin-left:4em;">Toujeo may be confused with Tanzeum [DSC], Tradjenta, Tresiba, Trulicity.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. <b>
<i>Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.</i></b></p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Insulin glargine is a clear solution, but it is NOT intended for IV or IM administration.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lantus [US, Canada, and multiple international markets] may be confused with Lanvis brand name for thioguanine [Canada and multiple international markets].</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F2114383"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F2114382"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Glucosidase Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with an alpha-glucosidase inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Insulins. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Insulins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Insulins. Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Glucose Lowering Effects: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Liraglutide: May enhance the hypoglycemic effect of Insulins. Management: Consider reducing the liraglutide dose if coadministered with insulin. Prescribing information for the Saxenda brand of liraglutide recommends a dose decrease of 50%. Monitor blood glucose for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Insulins may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metreleptin: May enhance the hypoglycemic effect of Insulins. Management: Insulin dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely for signs and symptoms of hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pioglitazone: May enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination. Management: If insulin is combined with pioglitazone, consider insulin dose reductions to avoid hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure, and consider pioglitazone dose reduction or discontinuation if heart failure occurs<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the hypoglycemic effect of Insulins. Management: Upon initiation of pramlintide, decrease mealtime insulin dose by 50% to reduce the risk of hypoglycemia. Monitor blood glucose frequently and individualize further insulin dose adjustments based on glycemic control.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosiglitazone: Insulins may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53275716"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients with diabetes mellitus who wish to conceive should use adequate contraception until glycemic control is achieved (ADA 2022). Because insulin glargine has an increased affinity to the insulin-like growth factor (IGF-I) receptor, there are theoretical concerns that it may contribute to adverse events when used during pregnancy (Blumer 2013). Patients who are stable on insulin glargine prior to conception may continue it during pregnancy. Theoretical concerns of adverse events associated with insulin glargine during pregnancy should be discussed prior to conception (Blumer 2013).</p></div>
<div class="block pri drugH1Div" id="F2114353"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Because insulin glargine has an increased affinity to the insulin-like growth factor (IGF-I) receptor, there are theoretical concerns that it may contribute to adverse events when used during pregnancy (Blumer 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia. To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2022; Blumer 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, insulin requirements tend to increase as pregnancy progresses, requiring frequent monitoring and dosage adjustments. Following delivery, insulin requirements decrease rapidly (ACOG 201 2018; ADA 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Insulin is the preferred treatment of type 1 and type 2 diabetes mellitus in pregnancy, as well as gestational diabetes mellitus when pharmacologic therapy is needed (ACOG 190 2018; ACOG 201 2018; ADA 2022). Pregnancy outcomes are similar following maternal use of insulin glargine and NPH insulin in pregnant patients with type 1 diabetes mellitus. Outcomes are likely to be similar in pregnant patients with type 2 diabetes and insulin glargine may be used when clinically indicated (ACOG 201 2018).</p></div>
<div class="block brc drugH1Div" id="F2110682"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">In a study using insulin glargine, both exogenous and endogenous insulin were present in breast milk (Whitmore 2012). Insulin is not systemically absorbed via breast milk but may provide local benefits to the infant GI tract (Anderson 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Appropriate glycemic control is required for the establishment of lactation in patients with diabetes mellitus (Anderson 2018). Breastfeeding provides metabolic benefits to mothers with type 1, type 2, and gestational diabetes mellitus as well as their infants; therefore, breastfeeding is encouraged (ACOG 201 2018; ADA 2022; Blumer 2013). Breastfeeding also influences maternal glucose tolerance; close monitoring of patients treated with insulin is recommended as dose adjustments may be required (ADA 2022; Anderson 2018). A small snack before breastfeeding may help decrease the risk of hypoglycemia in patients with pregestational diabetes (ACOG 201 2018; Reader 2004). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F8103878"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.</p></div>
<div class="block mop drugH1Div" id="F2114396"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Diabetes mellitus: Blood glucose (individualize frequency based on treatment regimen, hypoglycemia risk, and other patient-specific factors) (ADA 2022); electrolytes; renal function; hepatic function; weight.</p>
<p style="text-indent:-2em;margin-left:4em;">Gestational diabetes mellitus: Blood glucose 4 times daily (1 fasting and 3 postprandial) until well controlled, then as appropriate (ACOG 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Hospitalized patients: In patients who are eating, monitor blood glucose before meals and at bedtime; in patients who are not eating or are receiving continuous enteral feeds, monitor blood glucose every 4 to 6 hours (ADA 2022; ES [Umpierrez 2012]). More frequent monitoring may be required in some cases (eg, recurrent hypoglycemia, changes in nutrition, medication changes affecting glycemic control) (ES [Umpierrez 2012]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HbA<sub>1c</sub></i>: Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. <b>Note: </b>In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA<sub>1c</sub> is discordant with serum glucose levels or symptoms, consider evaluating HbA<sub>1c</sub> in combination with blood glucose levels and/or a glucose management indicator (ADA 2022; KDIGO 2020).</p></div>
<div class="block rer drugH1Div" id="F2114390"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommendations for glycemic control in patients with diabetes and/or hyperglycemia:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Nonpregnant adults (AACE [Samson 2023]; ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:4em;">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics). <b>Note</b>
<b>: </b>In patients using a continuous glucose monitoring system, a goal of time in range &gt;70% with time below range &lt;4% is recommended and is similar to a goal HbA<sub>1c</sub> &lt;7%.</p>
<p style="text-indent:-2em;margin-left:4em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics)</p>
<p style="text-indent:-2em;margin-left:4em;">Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): &lt;180 mg/dL (SI: &lt;10 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics)</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Older adults (≥65 years of age) (ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (ES [LeRoith 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">HbA<sub>1c</sub>: &lt;7% to 7.5% (healthy); &lt;8% (complex/intermediate health). <b>Note: </b>Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA<sub>1c</sub> level.</p>
<p style="text-indent:-2em;margin-left:4em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (healthy); 90 to 150 mg/dL (SI: 5 to 8.3 mmol/L) (complex/intermediate health); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:4em;">Bedtime capillary blood glucose: 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L) (healthy); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (complex/intermediate health); 110 to 200 mg/dL (SI: 6.1 to 11.1 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Pregnant patients:</i></p>
<p style="text-indent:-2em;margin-left:4em;">HbA<sub>1c</sub>: Pregestational diabetes (type 1 or type 2) (ADA 2023):</p>
<p style="text-indent:-2em;margin-left:6em;">Preconception (patients planning for pregnancy): &lt;6.5%.</p>
<p style="text-indent:-2em;margin-left:6em;">During pregnancy &lt;6% (if can be achieved without significant hypoglycemia) or &lt;7% if needed to prevent hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">Capillary blood glucose: <b>Note: </b>Less stringent targets may be appropriate if goals cannot be achieved without causing significant hypoglycemia (ADA 2023).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Gestational diabetes mellitus (ACOG 2018; ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:8em;">Fasting: &lt;95 mg/dL (SI: &lt;5.3 mmol/L).</p>
<p style="text-indent:-2em;margin-left:8em;">Postprandial: &lt;140 mg/dL (SI: &lt;7.8 mmol/L) (at 1 hour) or &lt;120 mg/dL (SI: &lt;6.7 mmol/L) (at 2 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pregestational diabetes mellitus (type 1 or type 2) (ADA 2023</i>
<i>):</i></p>
<p style="text-indent:-2em;margin-left:8em;">Fasting: 70 to 95 mg/dL (SI: 3.9 to 5.3 mmol/L).</p>
<p style="text-indent:-2em;margin-left:8em;">Postprandial: 110 to 140 mg/dL (SI: 6.1 to 7.8 mmol/L) (at 1 hour) <b>or</b> 100 to 120 mg/dL (SI: 5.6 to 6.7 mmol/L) (at 2 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hospitalized adult patients (ADA 2022):</i> Target glucose range: 140 to 180 mg/dL (SI: 7.8 to 10 mmol/L) (majority of critically ill and noncritically ill patients; &lt;140 mg/dL (SI: &lt;7.8 mmol/L) may be appropriate for selected patients, if it can be achieved without excessive hypoglycemia).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Perioperative care in adult patients (ADA 2022):</i> Target glucose range during perioperative period: Consider targeting 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Children and adolescents:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Preprandial glucose: 70 to 130 mg/dL (SI: 3.9 to 7.2 mmol/L) (ISPAD [Dimeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">Postprandial glucose: 90 to 180 mg/dL (SI: 5 to 10 mmol/L) (ISPAD [Dimeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">Bedtime/overnight glucose: 80 to 140 mg/dL (SI: 4.4 to 7.8 mmol/L) (ISPAD [Dimeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">HbA<sub>1c</sub>: &lt;7%; target should be individualized; a more stringent goal (&lt;6.5%) may be reasonable if it can be achieved without significant hypoglycemia; less aggressive goals (&lt;7.5% or &lt;8%) may be appropriate in patients who cannot articulate symptoms of hypoglycemia, cannot check glucose frequently, have a history of severe hypoglycemia, or have extensive comorbid conditions (ADA 2023; ISPAD [Dimeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">Surgical patients (ISPAD [Jefferies 2018]):</p>
<p style="text-indent:-2em;margin-left:6em;">Intraoperative: 90 to 180 mg/dL (SI: 5 to 10 mmol/L).</p>
<p style="text-indent:-2em;margin-left:6em;">ICU, postsurgery: 140 to 180 mg/dL (SI: 7.8 to 10 mmol/L).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Classification of hypoglycemia (ADA 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Level 1:</i> 54 to 70 mg/dL (SI: 3 to 3.9 mmol/L); hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Level 2:</i> &lt;54 mg/dL (SI: &lt;3 mmol/L); threshold for neuroglycopenic symptoms; requires immediate action.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Level 3:</i> Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.</p></div>
<div class="block pha drugH1Div" id="F2114388"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.</p>
<p style="text-indent:0em;margin-top:2em;">Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes; also directly inhibits the hydrolysis of triglycerides. In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.</p>
<p style="text-indent:0em;margin-top:2em;">Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either <i>E. coli</i> or <i>Saccharomyces cerevisiae</i>. Insulin glargine differs from human insulin by adding two arginines to the C-terminus of the B-chain in addition to containing glycine at position A21 in comparison to the asparagine found in human insulin. Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin glargine is a long-acting insulin analog.</p></div>
<div class="block phk drugH1Div" id="F2114391"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Onset and duration of hypoglycemic effects depend upon the route of administration (absorption and onset of action are more rapid after deeper IM injections than after SUBQ), site of injection (onset and duration are progressively slower with SUBQ injection into the abdomen, arm, buttock, or thigh respectively), volume and concentration of injection, and the preparation administered. Rate of absorption, onset, and duration of activity may be affected by exercise, presence of lipodystrophy, local blood supply, and/or temperature.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Onset of action: Lantus: 3 to 4 hours; Toujeo: 6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Basaglar, Lantus, insulin glargine-yfgn (Semglee, generic): Generally, 24 hours or longer; reported range (Lantus): 10.8 to &gt;24 hours (up to ~30 hours documented in some studies) (Heinemann 2000; Heise 2020); Toujeo: &gt;24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Slow; upon injection into the subcutaneous tissue, microprecipitates form which allow small amounts of insulin glargine to release over time.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Partially metabolized in the subcutaneous depot at the carboxyl terminus of the B chain to form two active metabolites, M1 (21A-Gly-insulin) and M2 (21A-Gly-des-30B-Thr-insulin).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Basaglar, Median: ~12 hours (manufacturer's labeling); Lantus, Semglee: Mean: subtle peak at ~10 to 12 hours (Heise 2020); Toujeo: Median: 12 to 16 hours following a single dose (maximum glucose lowering effect may take up to 5 days with repeat dosing) (manufacturer's labeling).</p></div>
<div class="block phksp drugH1Div" id="F51159883"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Altered kidney function: Insulin clearance may be reduced in patients with impaired renal function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869463"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Basaglar | Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Basaglar | Lantus | Optisulin | Toujeo</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Abasria | Lantus | Lantus Solostar | Semglee | Toujeo</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Lantus</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Glarine | Insul glargine | Insulet gn | Lantus | Larsulin | Semglee | Vibrenta</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Lantus | Lantus Solostar | Toujeo</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Basaglar | Glargilin | Lantus | Lantus Solostar | Toujeo</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Lantus</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Basaglar | Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Lantus | Recombinant Insulin Glargine</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Basaglar | Basalog | Glaritus | Lantus | Podevta | Toujeo</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Lantus | Semglee | Toujeo</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Lantus | Lantus Solostar | Toujeo</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Basaglar | Lantus | Recomulin g | Toujeo</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Basaglar | Bonglixan | Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Lantus | Lantus Solostar | Toujeo</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Lantus</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Lantus | Semglee | Toujeo</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Basalog | Lantus</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Insuline glargine | Lantus | Semglee | Toujeo | Toujeo doublestar</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Lantus | Semglee | Toujeo</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Lantus | Lantus Solostar | Toujeo</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Basaglar | Caprisulin log g | Ezelin | Lantus | Lantus Solostar | Sansulin log g</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Lantus</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Basaglar | Basalog | Basalog one | Glaritus | Glarvia | Lantus | Toujeo | Toujeo solostar</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Lantus | Toujeo solostar</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Insulin glargine bs ffp | Lantus</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Endulin select | Glaritus | Lantus | Lantus Solostar</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Basaglar kwikpen | Glarzia | Lantus | Lantus Solostar | Toujeo solostar</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Basaglar | Lantus | Toujeo solostar</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Basaglar | Glartus | Lantus | Lantus Solostar | Toujeo</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Basalog | Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Bonglixan | Galactus | Insulin glargine biomep | Insulin glargine novonordisk | Insulina glargina | Lantus | Toujeo | Valvey | Veluxus</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Basalog | Basalog one | Lantus | Lantus Solostar | Toujeo</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Lantus | Lantus Solostar | Semglee | Toujeo</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Lantus | Lantus Solostar | Toujeo</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Glaritus | Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Basagine | Basaglar | Glaritus | Glysolin g | Lantus | Lantus Solostar | Toujeo</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Basagine | Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Lantus | Semglee | Toujeo</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Basaglar | Lantus | Lantus Solostar | Semglee | Toujeo max solostar</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Lantus | Semglee | Toujeo</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Basaglar | Endulin | Endulin select | Glargine biocon | Glaritus | Lantus Solostar | Toujeo</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Basaglar | Basaglar KwikPen | Lantus | Lantus SoloStar | Toujeo SoloStar</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Toujeo</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Bazaglar | Lantus | Lantus Solostar | Toujeo | Toujeo solostar</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Lantus | Toujeo | Vivaro</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Lantus | Lantus Solostar | Semglee | Toujeo | Toujeo doublestar</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Basaglar | Basalog one | Lantus | Semglee | Toujeo</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Abasaglar | Lantus | Semglee | Toujeo</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Basalin | Glaritus | Lantus | Lantus Solostar | Toujeo</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Glargen | Lantus | Lantus Solostar | Toujeo solostar</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Basaglar | Glarin | Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Basaglar | Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Ailar | Lantus | Lantus Solostar | Toujeo</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Glaritus | Lantus | Lantus Solostar</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Basalog one | Lantus | Toujeo</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Insulina glargina | Lantus | Lantus Solostar</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Basaglar | Lantus | Optisulin | Semglee | Toujeo</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Endulin select</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-15867042">
<a name="15867042"></a>Alemzadeh R, Berhe T, Wyatt DT. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus. <i>Pediatrics</i>. 2005;115(5):1320-1324. doi:10.1542/peds.2004-1439<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/15867042/pubmed" id="15867042" target="_blank">15867042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29370047">
<a name="29370047"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 190: Gestational Diabetes Mellitus. <i>Obstet Gynecol</i>. 2018;131(2):e49-e64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/29370047/pubmed" id="29370047" target="_blank">29370047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30461693">
<a name="30461693"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 201: Pregestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;132(6):e228-e248. doi:10.1097/AOG.0000000000002960<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/30461693/pubmed" id="30461693" target="_blank">30461693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2019">
<a name="ADA.2019"></a>American Diabetes Association (ADA). <i>Diabetes Care</i>. 2019;42(suppl 1):S1-S193. http://care.diabetesjournals.org/content/42/Supplement_1. Accessed April 11, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2023">
<a name="ADA.2023"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023.<i> Diabetes Care.</i> 2023;45(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed February 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2020">
<a name="ADA.2020"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2020. <i>Diabetes Care</i>. 2020;43(suppl 1):S1-S212. https://care.diabetesjournals.org/content/43/Supplement_1. Accessed January 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2021">
<a name="ADA.2021"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2022.<i> Diabetes Care.</i> 2022;45(suppl 1):S1-S255. https://diabetesjournals.org/care/issue/45/Supplement_1. Accessed September 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29608329">
<a name="29608329"></a>Anderson PO. Treating diabetes during breastfeeding. <i>Breastfeed Med</i>. 2018;13(4):237-239. doi:10.1089/bfm.2018.0036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/29608329/pubmed" id="29608329" target="_blank">29608329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25590212">
<a name="25590212"></a>Apovian CM, Aronne LJ, Bessesen DH, et al; Endocrine Society. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(2):342-362. doi:10.1210/jc.2014-3415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/25590212/pubmed" id="25590212" target="_blank">25590212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007:42.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30425094">
<a name="30425094"></a>Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American Diabetes Association. <i>Diabetes Care</i>. 2018;41(12):2648-2668.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/30425094/pubmed" id="30425094" target="_blank">30425094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16911626">
<a name="16911626"></a>Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart. <i>Diabet Med</i>. 2006;23(8):879-886. doi:10.1111/j.1464-5491.2006.01913.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/16911626/pubmed" id="16911626" target="_blank">16911626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22699288">
<a name="22699288"></a>Baldwin D, Zander J, Munoz C, et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. <i>Diabetes Care</i>. 2012;35(10):1970-1974. doi:10.2337/dc12-0578<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/22699288/pubmed" id="22699288" target="_blank">22699288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17319470">
<a name="17319470"></a>Barnett AH. Insulin glargine in the treatment of type 1 and type 2 diabetes. <i>Vasc Health Risk Manag</i>. 2006;2(1):59-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/17319470/pubmed" id="17319470" target="_blank">17319470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Basaglar.1">
<a name="Basaglar.1"></a>Basaglar (insulin glargine) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Basaglar.2">
<a name="Basaglar.2"></a>Basaglar (insulin glargine) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26472948">
<a name="26472948"></a>Beck JK, Cogen FR. Outpatient management of pediatric type 1 diabetes. <i>J Pediatr Pharmacol Ther</i>. 2015;20(5):344-357. doi:10.5863/1551-6776-20.5.344<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/26472948/pubmed" id="26472948" target="_blank">26472948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12873291">
<a name="12873291"></a>Biesenbach G, Raml A, Schmekal B, Eichbauer-Sturm G. Decreased insulin requirement in relation to GFR in nephropathic type 1 and insulin-treated type 2 diabetic patients. <i>Diabet Med</i>. 2003;20(8):642-645. doi:10.1046/j.1464-5491.2003.01025.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/12873291/pubmed" id="12873291" target="_blank">12873291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24194617">
<a name="24194617"></a>Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/24194617/pubmed" id="24194617" target="_blank">24194617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. <a href="https://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html" target="_blank">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed January 9, 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935775">
<a name="24935775"></a>Chiang JL, Kirkman MS, Laffel LM, et al; Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. <i>Diabetes Care</i>. 2014;37(7):2034-54. doi:10.2337/dc14-1140<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/24935775/pubmed" id="24935775" target="_blank">24935775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14747243">
<a name="14747243"></a>Clement S, Braithwaite SS, Magee MF, et al; American Diabetes Association Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals. <i>Diabetes Care</i>. 2004;27(2):553-591. doi:10.2337/diacare.27.2.553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/14747243/pubmed" id="14747243" target="_blank">14747243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16126116">
<a name="16126116"></a>Colino E, López-Capapé M, Golmayo L, et al. Therapy with insulin glargine (Lantus) in toddlers, children and adolescents with type 1 diabetes. <i>Diabetes Res Clin Pract</i>. 2005;70(1):1-7. doi:10.1016/j.diabres.2005.02.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/16126116/pubmed" id="16126116" target="_blank">16126116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23359574">
<a name="23359574"></a>Copeland KC, Silverstein J, Moore KR, et al; American Academy of Pediatrics. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. <i>Pediatrics</i>. 2013;131(2):364-382. doi:10.1542/peds.2012-3494<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/23359574/pubmed" id="23359574" target="_blank">23359574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30051639">
<a name="30051639"></a>Couper JJ, Haller MJ, Greenbaum CJ, et al. ISPAD clinical practice consensus guidelines 2018: stages of type 1 diabetes in children and adolescents. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):20-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/30051639/pubmed" id="30051639" target="_blank">30051639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24829176">
<a name="24829176"></a>Cruijsen M, Koehestani P, Huttjes S, Leenders K, Janssen I, de Boer H. Perioperative glycaemic control in insulin-treated type 2 diabetes patients undergoing gastric bypass surgery. <i>Neth J Med</i>. 2014;72(4):202-209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/24829176/pubmed" id="24829176" target="_blank">24829176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29999222">
<a name="29999222"></a>Danne T, Phillip M, Buckingham BA, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):115-135. doi:10.1111/pedi.12718<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/29999222/pubmed" id="29999222" target="_blank">29999222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30291106">
<a name="30291106"></a>Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care.</i> 2018;41(12):2669-2701. doi:10.2337/dci18-0033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/30291106/pubmed" id="30291106" target="_blank">30291106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537523">
<a name="36537523"></a>de Bock M, Codner E, Craig ME, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. <i>Pediatr Diabetes</i>. 2022;23(8):1270-1276. doi:10.1111/pedi.13455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/36537523/pubmed" id="36537523" target="_blank">36537523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30058221">
<a name="30058221"></a>DiMeglio LA, Acerini CL, Codner E, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):105-114.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/30058221/pubmed" id="30058221" target="_blank">30058221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30619716">
<a name="30619716"></a>Eledrisi M, Suleiman NN, Salameh O, et al. Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus. <i>J Clin Transl Endocrinol</i>. 2018;15:35-36. doi:10.1016/j.jcte.2018.12.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/30619716/pubmed" id="30619716" target="_blank">30619716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022600">
<a name="32022600"></a>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. <i>Endocr Pract.</i> 2020;26(1):107-139. doi:10.4158/CS-2019-0472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25869408">
<a name="25869408"></a>Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015.<i> Endocr Pract.</i> 2015;21(suppl 1):1-87. doi:10.4158/EP15672.GLSUPPL<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/25869408/pubmed" id="25869408" target="_blank">25869408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10834424">
<a name="10834424"></a>Heinemann L, Hompesch B, Linkeschova R, et al. Time-Action Profile of the Long-Acting Insulin Analog Insulin Glargine (HOE901) in Comparison With Those of NPH and Placebo. <i>Diabetes Care</i>. 2000;23(5):644-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/10834424/pubmed" id="10834424" target="_blank">10834424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31724253">
<a name="31724253"></a>Heise T, Donnelly C, Barve A, Aubonnet P. Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL-1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus. <i>Diabetes Obes Metab</i>. 2020;22(4):521-529. doi:10.1111/dom.13919<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/31724253/pubmed" id="31724253" target="_blank">31724253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20144488">
<a name="20144488"></a>Housel AK, Shaw RF, Waterbury NV. Glucose control in patients with type 2 diabetes based on frequency of insulin glargine administration. <i>Diabetes Res Clin Pract</i>. 2010;88(2):e17-e19. doi:10.1016/j.diabres.2010.01.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/20144488/pubmed" id="20144488" target="_blank">20144488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IDF.1">
<a name="IDF.1"></a>International Diabetes Federation, International Society for Pediatric and Adolescent Diabetes. <i>Global IDF/ISPAD Guideline for Diabetes in Childhood and Adolescence</i>. 2011. Available at http://www.idf.org/global-idfispad-guideline-diabetes-childhood-and-adolescence. Last accessed: October 21, 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Inzucchi.2021">
<a name="Inzucchi.2021"></a>Inzucchi SE. Management of diabetes mellitus in hospitalized patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 7, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23164767">
<a name="23164767"></a>Jacobi J, Bircher N, Krinsley J, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. <i>Crit Care Med</i>. 2012;40(12):3251-3276. doi:10.1097/CCM.0b013e3182653269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/23164767/pubmed" id="23164767" target="_blank">23164767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30039617">
<a name="30039617"></a>Jefferies C, Rhodes E, Rachmiel M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Management of children and adolescents with diabetes requiring surgery. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):227-236. doi:10.1111/pedi.12733<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/30039617/pubmed" id="30039617" target="_blank">30039617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537521">
<a name="36537521"></a>Kapellen T, Agwu JC, Martin L, et al. ISPAD clinical practice consensus guidelines 2022: management of children and adolescents with diabetes requiring surgery. <i>Pediatr Diabetes</i>. 2022;23(8):1468-1477. doi:10.1111/pedi.13446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/36537521/pubmed" id="36537521" target="_blank">36537521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Khan.2022">
<a name="Khan.2022"></a>Khan NA, Ghali WA, Cagliero E. Perioperative management of blood glucose in adults with diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23106132">
<a name="23106132"></a>Kirkman M, Briscoe VJ, Clark N, et al. Diabetes in Older Adults: A Consensus Report. <i>J Am Geriatr Soc</i>. 2012. doi:10.1111/jgs.12035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/23106132/pubmed" id="23106132" target="_blank">23106132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kocurek.2018">
<a name="Kocurek.2018"></a>Kocurek B, Cryar K. Information for health care professionals switching between insulin products in disaster response situations. Approved by the American Diabetes Association, the Endocrine Society, and JDRF. https://www.diabetes.org/sites/default/files/2019-08/switching-between-insulin.pdf. Published August 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19417773">
<a name="19417773"></a>Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. <i>Int J Obes (Lond).</i> 2009;33(7):786-795. doi:10.1038/ijo.2009.79<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/19417773/pubmed" id="19417773" target="_blank">19417773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23997930">
<a name="23997930"></a>Kulozik F, Hasslacher C. Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin? <i>Ther Adv Endocrinol Metab</i>. 2013;4(4):113-121. doi:10.1177/2042018813501188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/23997930/pubmed" id="23997930" target="_blank">23997930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lantus.1">
<a name="Lantus.1"></a>Lantus (insulin glargine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lantus.2">
<a name="Lantus.2"></a>Lantus (insulin glargine) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22575407">
<a name="22575407"></a>McCall AL. Insulin therapy and hypoglycemia.<i> Endocrinol Metab Clin North Am.</i> 2012;41(1):57-87. doi:10.1016/j.ecl.2012.03.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/22575407/pubmed" id="22575407" target="_blank">22575407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31682518">
<a name="31682518"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists - executive summary. <i>Endocr Pract</i>. 2019;25(12):1346-1359. doi:10.4158/GL-2019-0406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/31682518/pubmed" id="31682518" target="_blank">31682518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19454396">
<a name="19454396"></a>Moghissi ES, Korytkowski MT, DiNardo M, et al; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. <i>Endocr Pract</i>. 2009;15(4):353-369. doi:10.4158/EP09102.RA<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/19454396/pubmed" id="19454396" target="_blank">19454396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22354457">
<a name="22354457"></a>Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. <i>Obes Surg</i>. 2012;22(5):740-748. doi:10.1007/s11695-012-0622-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/22354457/pubmed" id="22354457" target="_blank">22354457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Peters.2013">
<a name="Peters.2013"></a>Peters AP, Laffel L, eds. <i>Type 1 Diabetes Sourcebook</i>. American Diabetes Association; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22086363">
<a name="22086363"></a>Pichardo-Lowden A, Gabbay RA. Management of hyperglycemia during the perioperative period. <i>Curr Diab Rep</i>. 2012;12(1):108-118. doi:10.1007/s11892-011-0239-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/22086363/pubmed" id="22086363" target="_blank">22086363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31162534">
<a name="31162534"></a>Rahhal MN, Gharaibeh NE, Rahimi L, Ismail-Beigi F. Disturbances in insulin-glucose metabolism in patients with advanced renal disease with and without diabetes. <i>J Clin Endocrinol Metab</i>. 2019;104(11):4949-4966. doi:10.1210/jc.2019-00286<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/31162534/pubmed" id="31162534" target="_blank">31162534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28315574">
<a name="28315574"></a>Rajput R, Sinha B, Majumdar S, Shunmugavelu M, Bajaj S. Consensus statement on insulin therapy in chronic kidney disease. <i>Diabetes Res Clin Pract</i>. 2017;127:10-20. doi:10.1016/j.diabres.2017.02.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/28315574/pubmed" id="28315574" target="_blank">28315574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rashid.1">
<a name="Rashid.1"></a>Rashid K, Rehman KU, Anwer MS, Qureshi A, Basharat RA. Insulin requirement in diabetic patients with chronic renal failure due to diabetic nephropathy. <i>Biomedica</i>. 2004;20:79–84.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15461903">
<a name="15461903"></a>Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. <i>Curr Diab Rep</i>. 2004;4(5):370-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/15461903/pubmed" id="15461903" target="_blank">15461903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26566714">
<a name="26566714"></a>Reid T, Gao L, Gill J, et al. How much is too much? Outcomes in patients using high-dose insulin glargine. <i>Int J Clin Pract</i>. 2016;70(1):56-65. doi:10.1111/ijcp.12747<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/26566714/pubmed" id="26566714" target="_blank">26566714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm – 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Semglee.1">
<a name="Semglee.1"></a>Semglee (insulin glargine) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Semglee.2">
<a name="Semglee.2"></a>Semglee (insulin glargine) [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma ULC; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36161685">
<a name="36161685"></a>Shah AS, Zeitler PS, Wong J, et al. ISPAD clinical practice consensus guidelines 2022: type 2 diabetes in children and adolescents. <i>Pediatr Diabetes</i>. 2022;23(7):872-902. doi:10.1111/pedi.13409<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/36161685/pubmed" id="36161685" target="_blank">36161685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15616254">
<a name="15616254"></a>Silverstein J, Klingensmith G, Copeland K, et al; American Diabetes Association. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. <i>Diabetes Care</i>. 2005;28(1):186-212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/15616254/pubmed" id="15616254" target="_blank">15616254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20215452">
<a name="20215452"></a>Sobngwi E, Enoru S, Ashuntantang G, et al. Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis. <i>Diabetes Care</i>. 2010;33(7):1409-1412. doi:10.2337/dc09-2176<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/20215452/pubmed" id="20215452" target="_blank">20215452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28726299">
<a name="28726299"></a>Sundberg F, Barnard K, Cato A, et al. ISPAD Guidelines. Managing diabetes in preschool children. <i>Pediatr Diabetes</i>. 2017;18(7):499-517. doi:10.1111/pedi.12554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/28726299/pubmed" id="28726299" target="_blank">28726299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Toujeo.1">
<a name="Toujeo.1"></a>Toujeo (insulin glargine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Toujeo.2">
<a name="Toujeo.2"></a>Toujeo SoloStar and Toujeo DoubleStar (insulin glargine) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22223765">
<a name="22223765"></a>Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2012;97(1):16-38. doi:10.1210/jc.2011-2098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/22223765/pubmed" id="22223765" target="_blank">22223765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30724009">
<a name="30724009"></a>Umpierrez GE, Skolnik N, Dex T, Traylor L, Chao J, Shaefer C. When basal insulin is not enough: A dose-response relationship between insulin glargine 100 units/mL and glycaemic control. <i>Diabetes Obes Metab</i>. 2019;21(6):1305-1310. doi:10.1111/dom.13653<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/30724009/pubmed" id="30724009" target="_blank">30724009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.1">
<a name="Wexler.1"></a>Wexler DJ. Initial management of hyperglycemia in adults with type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 15, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.2">
<a name="Wexler.2"></a>Wexler DJ. Insulin therapy in type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 15, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22500167">
<a name="22500167"></a>Whitmore TJ, Trengove NJ, Graham DF, Hartmann PE. Analysis of insulin in human breast milk in mothers with type 1 and type 2 diabetes mellitus. <i>Int J Endocrinol</i>. 2012;2012:296368.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/22500167/pubmed" id="22500167" target="_blank">22500167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20345066">
<a name="20345066"></a>Youssef D, El Abbassi A, Woodby G, Peiris AN. Benefits of twice-daily injection with insulin glargine: a case report and review of the literature. <i>Tenn Med</i>. 2010;103(2):42-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/20345066/pubmed" id="20345066" target="_blank">20345066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29999228">
<a name="29999228"></a>Zeitler P, Arslanian S, Fu J, Pinhas-Hamiel O, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):28-46. doi:10.1111/pedi.12719<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-glargine-including-biosimilars-drug-information/abstract-text/29999228/pubmed" id="29999228" target="_blank">29999228</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9023 Version 437.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
